特色产业集群的成功绝非偶然，而是"产学研用"协同创新、政策精准扶持与资金有力支持共同作用的结 果。高校和科研机构的前沿研究成果，通过企业的转化应用，迅速变为现实生产力；"产学研用"的深度 融合，让创新不再是孤立的点，而是形成了紧密相连的创新链。同时，政府针对性地出台财政、金融、 人才等专项政策，为产业集群发展保驾护航，让企业在创新发展的道路上轻装上阵。 在全球经济格局深刻调整、国内经济转型升级的关键时期，特色产业集群的蓬勃发展，无疑成为中国经 济高质量发展的一把"金钥匙"，它不仅是当下经济增长的强劲动力，更是未来中国经济破局腾飞的关键 引擎。 未来，特色产业集群更是中国经济破局腾飞的关键所在。在全球科技竞争日益激烈的今天，谁能在新兴 产业领域占据先机，谁就能掌握经济发展的主动权。我国聚焦战略性新兴产业，推动特色产业集群向高 端化、智能化、绿色化发展，正是顺应时代潮流、把握发展机遇的战略之举。这不仅将提升我国产业在 全球价值链中的地位，还将为我国经济实现可持续发展奠定坚实基础。 特色产业集群并非新生事物，但如今它在我国的发展已实现了质的蜕变，绝非简单的产业聚集。回首往 昔，改革开放初期，我国凭借低成本劳动力和丰 ...

Group 1: Cloud Intelligence Technology - Yunzhisheng officially listed on the Hong Kong Stock Exchange on June 30, 2025, with the stock code "9678," becoming the first AGI stock in Hong Kong [2][5] - The company launched its first large language model, UniCore, based on BERT, and later developed the Shanhai model with 60 billion parameters, achieving significant performance in various evaluations [3][4] - Yunzhisheng's revenue from 2022 to 2024 was 601 million, 727 million, and 939 million CNY, with a compound annual growth rate (CAGR) of 25% [4] Group 2: Ophthalmic Biotechnology - Bokan Shiyun officially listed on the Hong Kong Stock Exchange on July 3, 2025, with the stock code "2592" [6] - The company focuses on developing differentiated drugs for major eye diseases using proprietary technology platforms [6] - Bokan Shiyun's core product CBT-001 is undergoing Phase III clinical trials in the US and China, aiming to provide non-invasive treatment for pterygium [6][7] Group 3: GPU Technology - Moore Threads submitted its prospectus for the Sci-Tech Innovation Board on June 30, 2025, focusing on self-developed GPUs for high-performance computing [8][9] - The company has achieved significant breakthroughs in GPU technology, with products nearing international advanced levels [10] - Revenue from 2022 to 2024 was 46 million, 124 million, and 438 million CNY, with a CAGR exceeding 200% [11] Group 4: Healthcare Payment Solutions - Meixin Health submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, becoming the largest multi-payment platform in China [14][15] - The company has saved patients approximately 6.7 billion CNY in out-of-pocket expenses by the end of 2024 [14] - Revenue from 2022 to 2024 was 1.069 billion, 1.255 billion, and 2.035 billion CNY, with a gross profit margin of 31.1%, 36.8%, and 35.8% respectively [16] Group 5: Industrial Robotics - Yifei Technology submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, focusing on industrial robots for the light industry [19][20] - The company is ranked fifth among domestic suppliers of industrial robots and related solutions in China [20] - As of June 21, 2025, Yifei Technology has over 400 million CNY in hand orders [22] Group 6: AI in Medical Imaging - Deshi Biotechnology submitted its prospectus for the Hong Kong Stock Exchange on June 29, 2025, focusing on AI in medical imaging [42] - The company's iMedImageTM model supports 19 types of medical imaging modalities, covering over 90% of clinical scenarios [43] - Revenue for 2023 and 2024 was 52.84 million and 70.35 million CNY, with gross profit margins of 71.0% and 65.5% respectively [48] Group 7: Antibody-Drug Conjugates - BlissBio Inc. submitted its prospectus for the Hong Kong Stock Exchange on June 29, 2025, focusing on next-generation ADCs for cancer treatment [50][51] - The company has four ADC candidates in clinical stages, with BB-1701 being the leading candidate for treating HER2-positive breast cancer [51][53] Group 8: Integrated Elderly Care Services - Puxiang Health submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, focusing on integrated medical and elderly care services [55] - The company is ranked second among integrated elderly care service providers in North China by revenue [56] - Revenue from 2022 to 2024 was 255 million, 422 million, and 500 million CNY [57]